To administratively DE-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552 (a), in preparation for september 30, 2026, closing of the period of…
Ended Awarded Last action
- Contract number
- 75N91021F00007
- Awardee
-
Roche Diagnostics Corporation UEI JDMDFEZBYH36
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- -$441
Award facts
- Contract value 0% obligated
- $43,570.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Indianapolis, IN 46250, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$441 | |
| Original award | $44,011 |
About this award
The National Cancer Institute issued a delivery order to Roche Diagnostics Corporation valued at $43,570.59 on July 26, 2021, with a completion date of August 26, 2021. This firm fixed-price delivery order was awarded without a set-aside designation and represents a child contract under a larger indefinite delivery vehicle. The contract is being performed in Castleton, Indiana, where Roche Diagnostics maintains significant operations. The award was structured to administratively de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a), in preparation for the September 30, 2026 closing of the period of availability for these fiscal year funds.
Roche Diagnostics Corporation is a foreign-owned manufacturer headquartered in Indianapolis, Indiana, specializing in in vitro diagnostics, laboratory instruments, reagents, and associated medical products. The company maintains an extensive federal contracting presence across multiple federal healthcare agencies, including the Department of Veterans Affairs, Defense Health Agency, Centers for Disease Control and Prevention, and the National Institutes of Health. Through its federal contracts, Roche supplies a comprehensive portfolio of diagnostic technologies including molecular diagnostic analyzers, histology staining systems, immunochemistry platforms, point-of-care testing devices, and specialized reagents for infectious disease detection and chronic condition management, along with associated maintenance and support services.
Description
To administratively DE-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552 (a), in preparation for september 30, 2026, closing of the period of availability of these fiscal year funds.
Quick answers
Who was awarded contract 75N91021F00007?
75N91021F00007 was awarded to Roche Diagnostics Corporation by National Cancer Institute (National Institutes of Health) on July 26, 2021.
How much is contract 75N91021F00007 worth?
The government has obligated -$441 on 75N91021F00007. Its current value, with exercised options, is $43,571.
Is contract 75N91021F00007 an order under another contract?
Yes. 75N91021F00007 is a delivery order under 75N91019D00038, an indefinite delivery contract.
Was contract 75N91021F00007 competed?
The extent of competition for 75N91021F00007 was not competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award